| Integrated genomic analyses of ovarian carcinoma Cancer Genome Atlas Research Network Nature 474 (7353), 609, 2011 | 4538 | 2011 |
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ... Nature 486 (7403), 395-399, 2012 | 1670 | 2012 |
| ARID1A mutations in endometriosis-associated ovarian carcinomas KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ... New England Journal of Medicine 363 (16), 1532-1543, 2010 | 1417 | 2010 |
| Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution SP Shah, RD Morin, J Khattra, L Prentice, T Pugh, A Burleigh, A Delaney, ... Nature 461 (7265), 809-813, 2009 | 1148 | 2009 |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non … KA Gelmon, M Tischkowitz, H Mackay, K Swenerton, A Robidoux, ... The lancet oncology 12 (9), 852-861, 2011 | 1027 | 2011 |
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 … FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ... PLoS med 7 (5), e1000279, 2010 | 912 | 2010 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 903 | 2018 |
| Ovarian carcinoma subtypes are different diseases: implications for biomarker studies M Köbel, SE Kalloger, N Boyd, S McKinney, E Mehl, C Palmer, S Leung, ... PLoS medicine 5 (12), e232, 2008 | 757 | 2008 |
| Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies CL Pearce, C Templeman, MA Rossing, A Lee, AM Near, PM Webb, ... The lancet oncology 13 (4), 385-394, 2012 | 742 | 2012 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 741 | 2018 |
| Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma C Tognon, SR Knezevich, D Huntsman, CD Roskelley, N Melnyk, ... Cancer cell 2 (5), 367-376, 2002 | 738 | 2002 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 622 | 2018 |
| Familial gastric cancer: overview and guidelines for management C Caldas, F Carneiro, HT Lynch, J Yokota, GL Wiesner, SM Powell, ... Journal of medical genetics 36 (12), 873-880, 1999 | 610 | 1999 |
| Mutation of FOXL2 in granulosa-cell tumors of the ovary SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ... New England Journal of Medicine 360 (26), 2719-2729, 2009 | 607 | 2009 |
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 580 | 2015 |
| Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research RC Fitzgerald, R Hardwick, D Huntsman, F Carneiro, P Guilford, V Blair, ... Journal of medical genetics 47 (7), 436-444, 2010 | 580 | 2010 |
| Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors Y Lou, PC McDonald, A Oloumi, S Chia, C Ostlund, A Ahmadi, A Kyle, ... Cancer research 71 (9), 3364-3376, 2011 | 567 | 2011 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 560 | 2018 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 539 | 2018 |
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers C Steidl, SP Shah, BW Woolcock, L Rui, M Kawahara, P Farinha, ... Nature 471 (7338), 377-381, 2011 | 503 | 2011 |
